Introduction
The choice and timing of primary and secondary treatment options in BCR-ABL-positive chronic myeloid leukemia (CML) in chronic phase has become increasingly complex. The constitutive tyrosine kinase activity of the BCR-ABL oncoprotein is selectively inhibited by imatinib which induces high rates of complete hematological and complete cytogenetic responses (CCyR) in the great majority of CML patients. 1 However, residual BCR-ABL transcripts can be detected in the vast majority of patients with CCyR and a definite cure has not been reported yet. 2 Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only approach generally accepted to achieve cure but its use is limited by age, availability of a suitable donor and transplant-related mortality and morbidity.
In patients pretreated with IFN or imatinib, the decision whether to proceed to allogeneic HSCT is influenced by hematological and cytogenetic response (CyR) and the individual risk for allogeneic HSCT. As a result of a transplant-related mortality (TRM) of 20-40% 3 and potentially substantial longterm morbidity, many investigators recommend drug treatment first, reserving allogeneic HSCT for very young patients, highrisk patients, and patients who fail to primary drug treatment. 4 However, the achievement of a CyR can take considerable time 5, 6 and the delay of transplantation might be associated with an inferior outcome. 3, 7 In analogy to acute myeloid leukemia, where TRM is lowest in patients transplanted in remission, 8 we sought to investigate whether this is true also for patients with CML. Here, we demonstrate that a CyR to IFN prior to or at HSCT is a strong and independently favorable prognostic factor for long-term survival after allogeneic HSCT.
Patients and methods

Study design
This study was conducted on all IFN pretreated and transplanted Ph-positive patients who have been enrolled within the randomized German CML studies I to III with predefined patient populations and randomly allocated pretreatments. CML studies I and II have been described previously. 6, 9, 10 Early transplantation was recommended for all patients with a donor who can tolerate the procedure. CML study III compares early allogeneic HSCT within the first year of diagnosis and best available drug treatment by genetic randomization.
Inclusion criteria
(i) Related or unrelated allogeneic HSCT, (ii) treatment with IFN prior to transplant for at least 3 months, and (iii) at least one cytogenetic analysis during IFN-treatment with an evaluation of X10 metaphases.
Patients
Out of 434 Ph-positive patients, who were transplanted within the prospective German CML studies I-III, 311 patients were transplanted after pretreatment with IFN. Out of these, 162 patients fulfilled the inclusion criteria for the current analysis. The main reasons for exclusion were lack of appropriate cytogenetic follow-up data (n ¼ 140) and IFN pretreatment for o3 months or lack of data regarding duration of IFN pretreatment (n ¼ 9), respectively. The minimal duration of 3 months for treatment with IFN was chosen because this is the interval for a meaningful first evaluation of CyR. The patients' baseline characteristics at diagnosis of chronic phase CML are summarized in Table 1 . Median observation time from diagnosis to last follow-up was 5.3 years; median observation time of living patients after allogeneic HSCT was 4.6 years.
Definitions and prognostic scores
The definition of disease status and the prognostic scoring systems regarding treatment with IFN ('New CML score') and allogeneic HSCT ('EBMT-score') were used as published previously. 3, 6, 9, 11 CyR was defined as following: complete CyR (CCyR) ¼ 0% Ph-positive metaphases, partial CyR ¼ 1-34% Ph-positive metaphases, major CyR ¼ complete or partial CyR, minor CyR ¼ 35-65% Ph-positive metaphases, minimal CyR ¼ 66-95% Ph-positive metaphases and no CyR ¼ 96-100% Ph-positive metaphases. A minimum of 10 evaluable metaphases was required for assessment of CyR. The best CyR ever achieved prior to allogeneic HSCT and the CyR at the time of HSCT (X10 metaphases evaluable p4 weeks before HSCT) were used to define the different response groups. Patients transplanted in accelerated phase or blast crisis were classified as no CyR at the time of HSCT. Relapse after HSCT was defined as (i) hematological recurrence of CML in peripheral blood or bone marrow, (ii) recurrence of the Ph þ clone (X10 metaphases evaluable or 2 subsequent evaluations p10 metaphases), and (iii) detection of BCR-ABL transcripts in previously negative patients or rising BCR-ABL transcripts in positive patients independent of cytogenetic remission status if it was followed by specific treatment, for example, donor lymphocyte infusions.
Statistical methods
With regard to the New CML score and the EBMT-score, patients' data at study entry and at the time of allogeneic HSCT were considered, respectively. At either time, variable values between different subgroups were compared using the w 2 test, Fisher's exact test, or Mann-Whitney U test, as appropriate. Survival probabilities were calculated by the Kaplan-Meier method and compared by the log-rank statistic. Log-rank test and Cox regression analyses were applied for univariate analyses. Cox regression with stepwise-selection procedure was used for multiple analyses in order to identify factors associated with survival after allogeneic HSCT. Variables considered for multiple analyses were the following: best cytogenetic response, disease phase and age at HSCT, duration of IFN-pretreatment, interval from discontinuation of IFN to HSCT, the new CML-Score, and conditioning regimen. Significance level for all analyses was a ¼ 0.05. Cumulative incidences of TRM and relapse were calculated under consideration of the competing risks, as suggested by Gooley. 12 For comparison of the cumulative incidences, the test of Gray was applied. 13 
Results
Pretreatment with IFN and CyR
One hundred and one out of 162 (62.3%) IFN treated and transplanted patients with Ph þ CML achieved a CyR on IFN, which was major (o35% Ph-positive metaphases) in 44 patients (27.2%). Out of these, 30 patients (18.5%) achieved a partial (1-34% Ph-positive metaphases) and 14 patients (8.6%) a complete CyR (0% Ph-positive metaphases). A major CyR occurred after a median of 350 days (range 88-1484). Mean applied daily dose of IFN was similar in patients with a CyR and patients without a CyR. The time of IFN pretreatment was significantly longer in patients with CyR (median 454 days, range 93-1711) than in patients without CyR (U-test: P ¼ 0.002, median 331 days, range 99-1587). The longest IFN-pretreatment was observed in patients with a major CyR (median 539 days, range 113-1711). Data on CyR at the time of HSCT (evaluated p 4 weeks before HSCT) were available in 54 of 132 chronic-phase patients. Twenty-five patients had an ongoing CyR (major CyR, n ¼ 10; minimal and minor CyR, n ¼ 15) at the time of HSCT. Twenty-nine patients had no CyR at the time of HSCT. Of those, 14 patients had lost a previous CyR, 15 patients had never achieved a CyR. In addition, 30 patients were transplanted in advanced phase.
Transplant procedure
Transplants were performed at 17 centers in Germany (140 patients) and three centers in Switzerland (16 patients). Six patients were transplanted elsewhere. Donors were genotypically HLA-identical siblings (n ¼ 53), partially HLA-matched extended family donors (n ¼ 9), and matched unrelated donors (n ¼ 100). Pretransplant characteristics are summarized in Table 1 . Survival probabilities were identical for patients with HLA-identical siblings and matched unrelated donors, allowing a joint analysis. At time of transplant the median age was 39 years (range 12-60), 19 patients (12%) had progressed to accelerated phase and 11 patients (7%) to blast crisis. Time to transplant was significantly longer in patients, who had achieved a CyR prior to transplant compared to those who had not (U-test: P ¼ 0.005, median time: 21 vs 16 months). Risk distribution according to the EBMT-score was identical for the different response groups ( Table 1 ). The vast majority of patients received standard conditioning for HSCT, either 12 Gy total bone irradiation (TBI) fractionated plus cyclophosphamide (n ¼ 100) or high-dose cyclophosphamide plus busulfan (n ¼ 51). Some patients received age adjusted standard conditioning (8 Gy TBI/cyclophosphamide/fludarabine, n ¼ 3) or other conditioning regimens (n ¼ 6). For GvHD prophylaxis (evaluable in 151 patients) a combination of methotrexate and cyclosporine was used in 123 patients (81%) and cyclosporine in combination with corticosteroids in 11 patients (7%). In all, 17 patients received other immunosuppressive therapy for GvHD-prophylaxis (e.g. mycophenolate mofetil, antithymocyte globulin, prednisone monotherapy). There was no difference between the patient groups as far as conditioning regimens and GvHD prophylaxis are concerned.
Survival
The overall 5-year survival after transplant was 58.1% (data not shown). Survival of patients with a CyR at any time prior to transplant was significantly longer than that of patients without CyR (log-rank test: P ¼ 0.019, 5-year survival probabilities: 63.6 vs 49.2%; Figure 1a ). The survival advantage was more pronounced in patients who had achieved a major CyR at any time than in patients with a minimal or minor CyR or patients without any CyR (log-rank test: P ¼ 0.040, 5-year survival: 69.4 vs 58.8 vs 49.2%; Figure 1b) .
Regarding the phase of disease and the status of CyR in chronic-phase patients at the time of HSCT (evaluable: n ¼ 84), the best survival probabilities were observed in the 25 patients with at least a minimal CyR (log-rank test: P ¼ 0.004, 5-year survival probability: 76%; Figure 1c ). Chronic-phase patients without CyR (n ¼ 29) revealed a 5-year survival of 37.4% and patients in advanced phase CML (n ¼ 30) of 26.7%. The two more unfavorable groups combined had a significantly inferior survival outcome than patients with at least a minimal CyR (logrank test: P ¼ 0.002). Analysis of the 29 patients transplanted in chronic-phase without CyR at the time of HSCT revealed a better but not significantly different survival between chronicphase patients who lost a previously achieved CyR (n ¼ 14) compared to patients who have never achieved any CyR (n ¼ 15) prior to HSCT (1-year survival probability: 64 vs 47%, 2-year survival probability: 57 vs 40%, log-rank test: P ¼ 0.226). Low patient numbers prevented a final conclusion.
TRM and causes of death
The overall cumulative incidence (CI) of TRM was 31% at 12 months. Causes of death are summarized in Table 1 . The TRM of patients without any CyR prior to HSCT was not different from patients with a major CyR or with a minor or minimal CyR (Gray test: P ¼ 0.131, TRM at 12 months: 37 vs 26 vs 28%; Figure 2a ). Regarding CyR and disease status at the time of HSCT, the CI of TRM in chronic-phase patients without CyR was similar to that in patients transplanted in advanced phase (Gray test: n.s., TRM at 12 months: 41 vs 50%; Figure 2b ). When both groups were combined, the CI of TRM was significantly higher than in patients who were transplanted in maintained CyR at the time of HSCT (Gray test: P ¼ 0.016, TRM at 12 months: 46 vs 20%).
Relapse after HSCT
Within the first 5 years, a relapse was observed in 12 of 162 patients (7.4%). One patient relapsed 73 months after HSCT. Overall, the median time to relapse was 19 months (range 2-73). According to any CyR prior to HSCT, the CI of relapse at 5 years was 8% in patients with no CyR (n ¼ 5), 11% in patients with a minor or minimal CyR (n ¼ 6) and 2% in patients with a major CyR (n ¼ 1), respectively (Gray-test: n.s.; Figure 2c ). According to CyR and disease status at the time of HSCT, the CI of relapse at 5 years was 17% in patients in advanced phase, 10% in chronic-phase patients without CyR (n ¼ 3) and 10% in patients with at least minimal CyR (n ¼ 2) (Gray-test: n.s.; Figure 2d ).
Prognostic relevance of prior CyR
In univariate analyses, CyR prior to transplantation was identified as a significant prognostic factor for survival after allogeneic HSCT (log-rank test: CyR vs no CyR, P ¼ 0.019; major CyR vs minimal or minor CyR vs no CyR, P ¼ 0.040). CyR and disease status at the time of transplant had a significant impact on outcome (log-rank test: at least minimal CyR vs chronic phase without CyR vs advanced phase, P ¼ 0.004). Other influential factors in the present study were the following: disease stage (log-rank test: Po0.001), age at diagnosis (Wald test: P ¼ 0.016), age at transplant (Wald test: P ¼ 0.012), and the EBMT-score (log-rank test: P ¼ 0.007). An influence on outcome after allogeneic HSCT could not be verified for the duration of pretreatment with IFN, different conditioning regimens, and strategies of GvHD prophylaxis (Table 2) .
To make sure that no hidden effect of a second covariate influenced the identified correlation between cytogenetic remission and survival after HSCT, multiple Cox regression was performed. The best model contained CyR status prior to HSCT (Wald test: P ¼ 0.026), age at HSCT (p44 years vs 444 years, Wald test: P ¼ 0.001), and disease stage at HSCT (Wald test: P ¼ 0.004). Thus, CyR induced by IFN was confirmed as an independent prognostic factor for survival after HSCT. Alternatively to this model, instead of age and disease status at time of transplant, the EBMT-score, comprising these two and three more variables, could be included (Wald test: CyR prior to HSCT: P ¼ 0.037, EBMT-score: P ¼ 0.008, Table 3 ). However, the w 2 value of the likelihood ratio statistic was much higher in the first model (27.18 vs 18.48, with five degrees of freedom in both cases) and, as part of the EBMT-score, more variables need to be considered in the second case. The duration of IFNpretreatment, interval from discontinuation of IFN to HSCT, the new CML-Score, and different conditioning regimens had no prognostic impact on survival in multiple analyses. Response to prior IFN and outcome after allogeneic HSCT O Maywald et al factors for poor outcome after allogeneic HSCT in CML 10, [14] [15] [16] while others have not. [17] [18] [19] However, the impact of a CyR to IFN prior to HSCT has never been taken into consideration. This is somehow surprising considering the fact that allogeneic HSCT is frequently only performed, if patients have failed to achieve or have lost a previous response to conventional drug treatment. This lack of data may be due to heterogeneous and relatively small patient populations in studies performed by single institutions, or to lack of data regarding prior treatment and response status in studies performed by transplant registries. 18 We have observed a superior survival in patients who were transplanted in maintained CyR at the time of HSCT. This survival advantage is most likely due to a lower TRM as compared to patients transplanted in chronic-phase without CyR or in advanced phase. However, a significant survival advantage was also seen in patients who achieved a CyR at any time prior to HSCT even if it was lost at the time of HSCT. This survival advantage was more pronounced in patients who had achieved a major CyR at any time than in patients with a minimal or minor CyR. The excellent outcome was seen despite the vast majority of patients received a delayed transplant due to prolonged administration of IFN. The number of relapses was too low to draw conclusions on relapse probabilities. Univariate and multiple analyses of factors associated with improved survival identified CyR both prior to and at transplant as a strong and independently favorable prognostic factor.
It is important to note that this study was conducted on patients who were part of three randomized trials with predefined patient populations and randomly allocated pretreatments. Transplant as the only curative treatment option was recommended to all suitable patients who had a donor, irrespective of risk group, treatment or achievement of a CyR. Transplant risks did not differ significantly between patients according to important parameters, such as EBMT score, disease phase, and age at HSCT. Differences in survival depending on CyR status remained statistically significant also in the presence of other significant parameters as assessed by multiple Cox regression.
It remains unclear, whether biological effects of IFN attributed to these observations or whether achievement of a CyR was more important. For patients with a CyR at any time prior to HSCT, it seems conceivable that the response to IFN might somehow predict the graft-versus-leukemia effect by similar influence on cell proliferation and immunomodulation, for example, by activating lymphocytes mediating antigen-specific and non-specific cytotoxicity. However, the beneficial effects were best in patients who were transplanted in CyR suggesting that the low tumor burden at time of HSCT may be the most advantageous factor.
The negative impact of a longer interval from diagnosis to transplant on TRM is based on the analysis of patients pretreated with busulfan or hydroxyurea. 20 However, early transplantation without awaiting a CyR was also suggested for patients treated with IFN, if an HLA-matched donor was available. 3, 7 A recent analysis has reported a lack of an association between transplantation within the first year of diagnosis and better disease-free survival. 18 This result was thought to be correlated to the fact that the analysis was limited to patients undergoing transplant within 4 years of diagnosis. Although recent analyses confirmed the favorable outcome of early transplantation, further studies are warranted, if transplant can be postponed safely in patients who respond to conventional drug treatment with a CyR.
This study suggests that the cytogenetic response to IFN has an important influence on outcome after allogeneic HSCT. Consequently, it will now be of particular interest, if this holds true also in patients with cytogenetic response to imatinib. Apart from potentially important parameters like duration and discontinuation of treatment, any forthcoming analysis investigating the influence of imatinib on outcome after HSCT should therefore take into account whether patients have responded or failed to treatment prior to HSCT.
As our results indicate that a low tumor burden at the time of HSCT leads to reduced TRM, and improved survival, allogeneic HSCT in CyR should be considered as a potential approach for suitable patients in defined situations even in the tyrosine kinase inhibitor era. This might relate to patients with high risk of progression despite initial response, to patients with early loss of molecular response or to places where the more favourable costs of HSCT as compared to continuous drug therapy need to be considered. 21, 22 Table 3 Associations between survival time after HSCT and patient characteristics identified using Cox regression with stepwise-selection procedure (n ¼ 146 patients evaluable) Response to prior IFN and outcome after allogeneic HSCT O Maywald et al
